Disease-Modifying Effects of Vincamine Supplementation in Drosophila and Human Cell Models of Parkinson's Disease Based on DJ-1 Deficiency.

Parkinson's disease (PD) is an incurable neurodegenerative disorder caused by the selective loss of dopaminergic neurons in the substantia nigra pars compacta. Current therapies are only symptomatic and are not able to stop or delay its progression. In order to search for new and more effective therapies, our group carried out a high-throughput screening assay, identifying several candidate compounds that are able to improve locomotor ability in DJ-1ß mutant flies (a Drosophila model of familial PD) and reduce oxidative stress (OS)-induced lethality in DJ-1-deficient SH-SY5Y human cells. One of them was vincamine (VIN), a natural alkaloid obtained from the leaves of Vinca minor. Our results showed that VIN is able to suppress PD-related phenotypes in both Drosophila and human cell PD models. Specifically, VIN reduced OS levels in PD model flies. Besides, VIN diminished OS-induced lethality by decreasing apoptosis, increased mitochondrial viability, and reduced OS levels in DJ-1-deficient human cells. In addition, our results show that VIN might be exerting its beneficial role, at least partially, by the inhibition of voltage-gated sodium channels. Therefore, we propose that these channels might be a promising target in the search for new compounds to treat PD and that VIN represents a potential therapeutic treatment for the disease.

Identification of potential therapeutic compounds for Parkinson's disease using Drosophila and human cell models.

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. It is caused by a loss of dopaminergic neurons in the substantia nigra pars compacta, leading to a decrease in dopamine levels in the striatum and thus producing movement impairment. Major physiological causes of neurodegeneration in PD are oxidative stress (OS) and mitochondrial dysfunction; these pathophysiological changes can be caused by both genetic and environmental factors. Although most PD cases are sporadic, it has been shown that 5-10% of them are familial forms caused by mutations in certain genes. One of these genes is the DJ-1 oncogene, which is involved in an early-onset recessive PD form. Currently, PD is an incurable disease for which existing therapies are not sufficiently effective to counteract or delay the progression of the disease. Therefore, the discovery of alternative drugs for the treatment of PD is essential. In this study we used a Drosophila PD model to identify candidate compounds with therapeutic potential for this disease. These flies carry a loss-of-function mutation in the DJ-1ß gene, the Drosophila ortholog of human DJ-1, and show locomotor defects reflected by a reduced climbing ability. A pilot modifier chemical screen was performed, and several candidate compounds were identified based on their ability to improve locomotor activity of PD model flies. We demonstrated that some of them were also able to reduce OS levels in these flies. To validate the compounds identified in the Drosophila screen, a human cell PD model was generated by knocking down DJ-1 function in SH-SY5Y neuroblastoma cells. Our results showed that some of the compounds were also able to increase the viability of the DJ-1-deficient cells subjected to OS, thus supporting the use of Drosophila for PD drug discovery. Interestingly, some of them have been previously proposed as alternative therapies for PD or tested in clinical trials and others are first suggested in this study as potential drugs for the treatment of this disease.

Antioxidant compound supplementation prevents oxidative damage in a Drosophila model of Parkinson's disease.

Loss-of-function mutations in the DJ-1 gene are linked to rare autosomal recessive forms of parkinsonism. In Drosophila, two DJ-1 orthologs have been identified, DJ-1α and DJ-1ß. Several studies have shown that DJ-1ß mutant flies are viable and fertile but exhibit age-dependent locomotor defects, shortened life span, and enhanced sensitivity to toxins that induce oxidative stress response compared to control flies. We also demonstrated that long-term dietary supplementation with antioxidant compounds was effective at increasing life-span values of DJ-1ß mutants. These results, together with high levels of oxidative stress markers detected in newly eclosed DJ-1ß mutant flies compared to controls, led to the proposal that the life-span phenotype was in part due to defects in the oxidative stress response. To further demonstrate this assumption, we analyzed in detail several markers of oxidative stress in control and DJ-1ß mutant flies, either untreated or treated with antioxidant compounds. First, we quantified global reactive oxygen species (ROS) as well as H2O2 production; next we measured the activity of several enzymes that respond to oxidative stress such as catalase and superoxide dismutase; and finally we determined protein oxidative damage. Our results showed that DJ-1ß mutants exhibit elevated ROS production and protein oxidative damage as well as decreased antioxidant enzyme activity compared to control flies of the same age, which is consistent with the proposed protective role of DJ-1ß against oxidative stress. We found that supplementation with either α-tocopherol or the general antioxidant compound ascorbic acid (vitamin C) increased catalase activity and decreased H2O2 and oxidized protein levels in DJ-1ß mutants and control flies, but it led to decreased superoxide dismutase activity, maybe as a consequence of a global reduction in oxidative stress. However, α-tocopherol supplementation specifically reduced global ROS production in DJ-1ß mutant flies. This study confirms the important role of DJ-1ß in oxidative stress response in Drosophila, especially at the level of H2O2 detoxification, and provides evidence that early antioxidant supplementation is an effective treatment to suppress phenotypes in DJ-1ß mutants partly by reducing oxidative damage.